Clinical trials
Waldenstrom Macroglobulinemia clinical trials
Below are recruiting waldenstrom macroglobulinemia clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
AmiensAges 18 years+ - NCT05099471RecruitingPhase 2
Venetoclax plus rituximab for Waldenström’s macroglobulinemia
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
BielefeldAges 18 years+ - NCT05640102Recruiting
Study of zanubrutinib in Waldenström macroglobulinemia
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Huntsville, AlabamaAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT04898647Recruiting
Study of blood thickness in Waldenström’s disease
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
AmiensAges 18 years+ - NCT07231952RecruitingPhase 2
Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Boston, MassachusettsAges 18 years+ - NCT03697356RecruitingPhase 2
Rituximab plus VRD, then lenalidomide to treat Waldenstrom’s
This Phase 2 study tests a treatment plan that starts with rituximab plus VRD (bortezomib, and reduced-dose drugs in the VRD group), then uses lenalidomide for maintenance to help control Waldenstrom’s macroglobulinemia. It may help people who need treatment because their disease is measurable.
Busan, Sue-guAges 19 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Tucson, ArizonaAges 18 years+ - NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Bethesda, MarylandAges 18–110 - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT04061512RecruitingPhase 2/Phase 3
Rituximab plus ibrutinib versus standard steroids plus rituximab
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
BathAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05093153Recruiting
Registry for adults with IgM blood protein conditions
This study is a registry that collects information about adults with certain IgM-related blood conditions. It may help doctors better understand these illnesses and improve future care.
Mérida, BadajozAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Duarte, CaliforniaAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05914662RecruitingPhase 2
Zanubrutinib plus BR for newly diagnosed symptomatic WM
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06510491RecruitingPhase 2
Epcoritamab for relapsed Waldenstrom macroglobulinemia
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
Boston, MassachusettsAges 18 years+ - NCT06561347RecruitingPhase 2
Zanubrutinib with bendamustine and rituximab for untreated Waldenstrom macroglobulinemia
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06860880Recruiting
Personalized program to fight cancer-related fatigue
This trial tests a personalized supportive care program that combines exercise, nutrition, and coaching to help reduce fatigue in people with certain slow-growing lymphomas. It aims to improve energy and quality of life.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Waldenstrom Macroglobulinemia trials by city
Studies with a site in or near these metro areas.
Waldenstrom Macroglobulinemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for waldenstrom macroglobulinemia?
- Yes. Clin2 currently lists 28 recruiting waldenstrom macroglobulinemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a waldenstrom macroglobulinemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a waldenstrom macroglobulinemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.